Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to 18.64%.

  • Sanara MedTech's EBITDA Margin rose 68100.0% to 18.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.72%, marking a year-over-year increase of 7000.0%. This contributed to the annual value of 3.11% for FY2024, which is 29100.0% up from last year.
  • As of Q3 2025, Sanara MedTech's EBITDA Margin stood at 18.64%, which was up 68100.0% from 10.32% recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's EBITDA Margin registered a high of 18.64% during Q3 2025, and its lowest value of 47.19% during Q4 2021.
  • Its 5-year average for EBITDA Margin is 10.13%, with a median of 7.14% in 2023.
  • Per our database at Business Quant, Sanara MedTech's EBITDA Margin tumbled by -297600bps in 2021 and then skyrocketed by 320800bps in 2023.
  • Sanara MedTech's EBITDA Margin (Quarter) stood at 47.19% in 2021, then soared by 58bps to 19.69% in 2022, then soared by 113bps to 2.54% in 2023, then crashed by -460bps to 9.14% in 2024, then surged by 304bps to 18.64% in 2025.
  • Its EBITDA Margin was 18.64% in Q3 2025, compared to 10.32% in Q2 2025 and 2.81% in Q1 2025.